Ariel Gordin

1.4k total citations
40 papers, 1.1k citations indexed

About

Ariel Gordin is a scholar working on Cardiology and Cardiovascular Medicine, Neurology and Epidemiology. According to data from OpenAlex, Ariel Gordin has authored 40 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 8 papers in Neurology and 8 papers in Epidemiology. Recurrent topics in Ariel Gordin's work include Parkinson's Disease Mechanisms and Treatments (8 papers), Neurological disorders and treatments (6 papers) and Thyroid Disorders and Treatments (4 papers). Ariel Gordin is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (8 papers), Neurological disorders and treatments (6 papers) and Thyroid Disorders and Treatments (4 papers). Ariel Gordin collaborates with scholars based in Finland, United Kingdom and Germany. Ariel Gordin's co-authors include Stig Sundberg, Seppo Kaakkola, Antti Kohvakka, Anna-Leena Kirkkola, Heikki Vapaatalo, Seppo Salminen, Simo Siitonen, Pekka T. Männistö, Mika Scheinin and Kirsti Tiihonen and has published in prestigious journals such as The Lancet, Biochemical and Biophysical Research Communications and The American Journal of Cardiology.

In The Last Decade

Ariel Gordin

39 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ariel Gordin Finland 20 257 256 188 180 142 40 1.1k
Emília Antúnez Spain 16 279 1.1× 148 0.6× 52 0.3× 149 0.8× 132 0.9× 24 1.2k
Karin Kraft Germany 17 106 0.4× 189 0.7× 53 0.3× 112 0.6× 193 1.4× 90 932
P Rhodes United States 17 85 0.3× 213 0.8× 71 0.4× 32 0.2× 585 4.1× 48 1.8k
Larissa Constantino Brazil 25 175 0.7× 369 1.4× 32 0.2× 53 0.3× 135 1.0× 57 1.7k
Sofia Viana Portugal 19 104 0.4× 426 1.7× 46 0.2× 52 0.3× 92 0.6× 50 1.1k
Leo Galland United States 12 56 0.2× 422 1.6× 77 0.4× 45 0.3× 280 2.0× 26 1.4k
Zeinab Ghorbani Iran 22 91 0.4× 387 1.5× 60 0.3× 62 0.3× 114 0.8× 83 1.8k
Alan L. Miller United States 13 48 0.2× 162 0.6× 50 0.3× 54 0.3× 106 0.7× 21 1.1k
J.L. Urbain United States 15 49 0.2× 151 0.6× 66 0.4× 75 0.4× 195 1.4× 29 1.8k
Waseem Ashraf Pakistan 19 397 1.5× 269 1.1× 39 0.2× 38 0.2× 74 0.5× 78 1.5k

Countries citing papers authored by Ariel Gordin

Since Specialization
Citations

This map shows the geographic impact of Ariel Gordin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ariel Gordin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ariel Gordin more than expected).

Fields of papers citing papers by Ariel Gordin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ariel Gordin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ariel Gordin. The network helps show where Ariel Gordin may publish in the future.

Co-authorship network of co-authors of Ariel Gordin

This figure shows the co-authorship network connecting the top 25 collaborators of Ariel Gordin. A scholar is included among the top collaborators of Ariel Gordin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ariel Gordin. Ariel Gordin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gordin, Ariel & David J. Brooks. (2007). Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease. Journal of Neurology. 254(S4). IV37–IV48. 9 indexed citations
2.
Deuschl, Günther, et al.. (2007). Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing‐off. Movement Disorders. 22(11). 1550–1555. 23 indexed citations
3.
Paija, Outi, Kari Laine, Mika Leinonen, et al.. (2005). Entacapone Increases Levodopa Exposure and Reduces Plasma Levodopa Variability When Used With Sinemet CR. Clinical Neuropharmacology. 28(3). 115–119. 22 indexed citations
4.
Gordin, Ariel, Seppo Kaakkola, & H. Teräväinen. (2003). Position of COMT inhibition in the treatment of Parkinson's disease.. PubMed. 91. 237–50. 18 indexed citations
5.
Lyytinen, Jukka, A. Sovijärvi, Seppo Kaakkola, Ariel Gordin, & H. Teräväinen. (2001). The Effect of Catechol-O-Methyltransferase Inhibition with Entacapone on Cardiovascular Autonomic Responses in L-Dopa-treated Patients with Parkinson's Disease. Clinical Neuropharmacology. 24(1). 50–57. 27 indexed citations
6.
Nutt, John G., et al.. (2001). The Effects of Different Repeated Doses of Entacapone on the Pharmacokinetics of L-Dopa and on the Clinical Response to L-Dopa in Parkinson's Disease. Clinical Neuropharmacology. 24(3). 150–157. 38 indexed citations
7.
Trocóniz, Iñaki F., et al.. (1998). Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Clinical Pharmacology & Therapeutics. 64(1). 106–116. 24 indexed citations
8.
Smith, Lance A., Ariel Gordin, Peter Jenner, & C. D. Marsden. (1997). Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets. Movement Disorders. 12(6). 935–945. 40 indexed citations
9.
Illi, Ari, et al.. (1996). Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: Effects on hemodynamics and catecholamine metabolism in healthy volunteers*. Clinical Pharmacology & Therapeutics. 59(4). 450–457. 33 indexed citations
10.
Illi, Ari, et al.. (1995). The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine*. Clinical Pharmacology & Therapeutics. 58(2). 221–227. 24 indexed citations
11.
Kaakkola, Seppo, Ariel Gordin, & Pekka T. Männistö. (1994). General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. General Pharmacology The Vascular System. 25(5). 813–824. 104 indexed citations
12.
Tuominen, Raimo K., R Lehtinen, Juha Peltola, et al.. (1991). Penetration of erythromycin into periapical lesions after repeated doses of erythromycin acistrate and erythromycin stearate: A pilot study. Oral Surgery Oral Medicine Oral Pathology. 71(6). 684–688. 2 indexed citations
13.
Kaukoranta-Tolvanen, Suvi-Sirkku E., et al.. (1989). Effect of Erythromycin Acistrate and Erythromycin Stearate on Human Colonic Microflora. Scandinavian Journal of Infectious Diseases. 21(6). 717–720. 4 indexed citations
14.
Auvinen, O, et al.. (1987). Trimethoprim and Sulfadiazine Penetration into Bile and Gallbladder in Acute Cholecystitis. Chemotherapy. 33(3). 160–164. 3 indexed citations
15.
Tiihonen, Kirsti, et al.. (1987). Vasodilatory Effects of Carvedilol and Pindolol. Journal of Cardiovascular Pharmacology. 10. S76–S80. 22 indexed citations
16.
Sundberg, Stig, Kirsti Tiihonen, & Ariel Gordin. (1987). Vasodilatory Effects of Carvedilol and Pindolol. Journal of Cardiovascular Pharmacology. 10(Supplement). S76–S80. 1 indexed citations
17.
Gordin, Ariel, et al.. (1987). Comparison of Three- and Ten-day Regimens with a Sulfadiazine-Trimethoprim Combination and Pivmecillinam in Acute Lower Urinary Tract Infections. Scandinavian Journal of Infectious Diseases. 19(1). 97–102. 17 indexed citations
18.
Perhoniemi, Vesa, et al.. (1984). Effects of Flunarizine and Pentoxifylline on Walking Distance and Blood Rheology in Claudication. Angiology. 35(6). 366–372. 36 indexed citations
19.
Fyhrquist, Frej, Matti Klockars, Ariel Gordin, T Törnroth, & B Kock. (1980). Hyperreninemia, Lysozymuria, and Erythrocytosis in Fanconi Syndrome with Medullary Cystic Kidney. Acta Medica Scandinavica. 207(1-6). 359–365. 4 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emília Antúnez Breakdown of academic impact, for papers by Karin Kraft Breakdown of academic impact, for papers by P Rhodes Breakdown of academic impact, for papers by Larissa Constantino Breakdown of academic impact, for papers by Sofia Viana Breakdown of academic impact, for papers by Leo Galland Breakdown of academic impact, for papers by Zeinab Ghorbani Breakdown of academic impact, for papers by Alan L. Miller Breakdown of academic impact, for papers by J.L. Urbain Breakdown of academic impact, for papers by Waseem Ashraf
Rankless by CCL
2026